Samsung Bioepis said on the 27th that it recently held an inflammatory bowel disease symposium in Gangnam District, Seoul, and introduced Epyztek. Epyztek treats autoimmune diseases such as psoriatic arthritis and Crohn's disease. It is a Stelara biosimilar (biosimilar) developed by global drugmaker Janssen.
Samsung Bioepis rolled out Epyztek in July 2024 at a price 40% lower than Stelara. More recently, it won approval for an Epyztek prefilled pen format. It is more convenient for patients to administer than the existing prefilled syringe.
The symposium shared the latest research and clinical findings with about 70 domestic gastroenterologists. Chung Jinhan, a vice president at Samsung Bioepis, said, "We will communicate with frontline medical staff and provide patients with optimal treatment."